The possible use of terpene compounds in DC immunotherapy against cancer

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 4, Issue 1, 2010, Pages 69-74

  Takei, Masao ^a   Umeyama, Akemi ^b   Lee, Je Jung ^a,c  

^a Chonnam National University   (South Korea)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c Chonnam National University Medical School   (South Korea)

Author keywords

Cancer immunotherapy; Dendritic cells; IL 12; Terpene compounds; Toll like receptor (TLR)

Indexed keywords

16 PHYLLOCLADANOL; CANCER VACCINE; DENDRITIC CELL VACCINE; DITERPENE; GAMMA INTERFERON; INTERLEUKIN 12; PACLITAXEL; PHOSPHORYL LIPID A; SANDARACOPIMARADIENE 3 BETA OL; SANDARACOPIMARIC ACID; SESQUITERPENE; TERPENE DERIVATIVE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; URACINIC ACID C;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL INTERACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; HEMATOLOGIC MALIGNANCY; HUMAN; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 77951142480     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221410790226783     Document Type: Review

References (45)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 106: 245-252.
2. Lanzavecchia A, Sallustoa AF. Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263-266. (Pubitemid 32772609)
3. Mellman I, Steinman RM. Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001; 106: 2555-2558. (Pubitemid 32772607)
4. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: The near future. Int J Cancer 2001; 95: 459-473. (Pubitemid 32979535)
5. Forster R, Schubel A, Breitfeld D. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23-33. (Pubitemid 29468627)
6. Nolte MA, van Olffen RW, van Gisbergen KPJM, et al. Timing and tuning of CD27-CD70 interactions: The impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009: 229: 216-231.
7. Stockinger B, Veldhoen M, Martin B. Th17 cells: Linking innate and adaptive immunity. Semin Immunol 2007: 19: 353-361. (Pubitemid 351274048)
8. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008: 10: 206-213.
9. O'Garra A, Murphy K. T-cell subsets in autoimmunity. Curr Opin 1993: 5: 880-886.
10. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752. (Pubitemid 26324129)
11. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 189: 821-829. (Pubitemid 29189687)
12. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999; 96: 9305-9310. (Pubitemid 29374750)
13. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007: 13: 4677-4685. (Pubitemid 47294773)
14. Fong L, Engelman EG. Debdritic cells in cancer immunotherapy. Annu Rev Immunol 2000: 18: 245-273.
15. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naïve CD8T cells: Dissociating proliferation and development of effector function. J Exp Med 2003: 197: 1141-1151.
16. Kalinski P, Hilkens CM, Wierebga EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today 1999: 20: 561-567.
17. Yoo JK, Cho JH, Lee SW, et al. IL-12 procides proliferation and survival signals to murine CD+4T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 2002: 169: 3637-3643.
18. Wesa A, Kalinski P, Kirkwood JM, et al Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient Th1-type antimelanoma CD4+ T cell responses in vitro. J Immunother 2007: 30: 75082. (Pubitemid 46052205)
19. Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002: 13: 155-168.
20. Braughler, M.J., Kumar, P., Storkus, W.J., Okada, H.: US20090123441A1 (2009).
21. Waldmann TA. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 2006: 6: 595-601. (Pubitemid 44134092)
22. Severa M, Remoli ME, Giacomini E, et al. Sensitization to TLR7 agonist in IFN-β-preactivated dendritic cells. J Imuunol 2007: 178: 6208-6216. (Pubitemid 46717403)
23. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000: 13: 715-725.
24. Lastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007: 25: 221-242.
25. McKenzie BS, Kastelei RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006: 2:7: 17-23.
26. Kikly K, Liu L, Na S, et al. The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006: 18: 670-675.
27. Okamoto M, Sato M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest 2003; 50:9-24. (Pubitemid 36717333)
28. Kaspenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3(12):984-993.
29. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589: 1-13.
30. Akira S, Takeda K, Kaisho T. Toll-like receptors; critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680. (Pubitemid 32747155)
31. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-787.
32. Akdis CA, Kussebi F, Pulendran B, et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003: 33: 2717-2726.
33. Alexopoulou L, Holt AC, Medzhitov R, Favell RA. Recognition of double-stranded RNA and activation of NF-β by Toll-like receptors 3. Nature 2001; 413: 732-738. (Pubitemid 33009951)
34. Ismaili J, Rennesson J, Aksoy E, et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002: 168: 926-932.
35. Hemmi H, Kaisho T, Takeuchi O, et al. Small-anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200.
36. Stary G, Bangerd C, Tauber M et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204: 1441-1451.
37. Brasel, K., Lyman, S. D., Maraskovsky, E., McKenna, Hilary R., Lynch, D.H., Maliszewski, C. R.: US20090075886 (2009).
38. Liby KT, Yore MM, Sporn MB. Triterpenoids and retinoid as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007: 7: 357-368.
39. Bowen, I.D., Ali, A. Y.: US20070259056 (2007).
40. Takei M, Umeyama A, Arihara S. T-cadinol and calamenene induce dendritic cells from human monocytes and drive Th1 polarization. Eur J Pharmacol 2006; 537: 190-199.
41. Takei M, Umeyama A, Shoji N, Hashimoto T. Diterpenes drive Th1 polarization depending on IL-12. Int Immunopharmacol 2008; 8: 1602-1608.
42. Takei M, Umeyama A, Shoji N, Hashimoto T. Diterpene, 16-phyllocladanol enhances TH1 polarization induced by LPS-primed DC, but not TNF-α-primed DC. Biochem Biophys Res Commun 2008; 370: 6-10.
43. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Mouse Toll-like receptor 4, MD-2 complex mediates lipopolysaccharide-mimetic signal trans diction by Taxol. J Biol Chem 2000; 275: 2251-2254.
44. Umeyama A, Hashimoto T, Takei M, et al. Triterpene ester from Uncaria rhynchophylla drive potent Th1 polarization depending on IL-12. Biol Pharm Bull 2009; [in press].
45. Hasumi, K.: US20090074713 (2009).